Fox Run Management, L.L.C. Ascendis Pharma A/S Transaction History
Fox Run Management, L.L.C.
- $588 Million
- Q3 2025
A detailed history of Fox Run Management, L.L.C. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 1,666 shares of ASND stock, worth $340,530. This represents 0.06% of its overall portfolio holdings.
Number of Shares
1,666Holding current value
$340,530% of portfolio
0.06%Shares
4 transactions
Others Institutions Holding ASND
# of Institutions
318Shares Held
65MCall Options Held
476KPut Options Held
142K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.1 Billion35.1% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.26MShares$1.08 Billion4.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.11MShares$1.04 Billion13.88% of portfolio
-
Janus Henderson Group PLC London, X04.32MShares$884 Million0.41% of portfolio
-
Lombard Odier Asset Management (Europe) LTD London, X04.27MShares$873 Million0.89% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.4B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...